5 Top Gainers In Healthcare Sector (GTHX, AGE, OVID...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. G1 Therapeutics Inc. (GTHX)

Gained 24.05% to close Tuesday's (June 18) trading at $24.50.

News: The Company announced promising preliminary overall survival results from a randomized phase II trial of Trilaciclib in combination with chemotherapy in women with metastatic triple-negative breast cancer.

The trial demonstrated that women with metastatic triple-negative breast cancer (mTNBC) lived significantly longer when receiving Trilaciclib and chemotherapy compared with women receiving chemotherapy alone.

Trilaciclib is being evaluated in patients with small-cell lung cancer.

Near-term Catalysts:

-- Detailed data from the phase II trial of Trilaciclib in combination with chemotherapy in women with metastatic triple-negative breast cancer will be presented at a medical meeting later this year. -- The Company expects to submit marketing applications for Trilaciclib in the U.S. and Europe for myelopreservation in small cell lung cancer in 2020.

2. Immuron Limited (IMRN)

Gained 15.63% to close Tuesday's trading at $2.96.

News: No news

Products & Pipeline:

The Company has one marketed product, Travelan, a novel, over the counter ("OTC") product for the prevention of Travellers' Diarrhea. This product brings in annual revenue of over AU$1 million.

The investigational drugs in clinical testing include IMM-124E and IMM-529.

IMM-124E is under phase II trials in the indications of nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and pediatric nonalcoholic fatty liver disease (NAFLD). The company has plans to develop a U.S. registration dossier for IMM-124E for Travelers' Diarrhea.

IMM-529 is under a phase I/II trial in patients with Clostridium difficile infections (CDI).

3. AgeX Therapeutics Inc. (AGE)

Gained 15.48% to close Tuesday's trading at $3.58.

News: No news

Pipeline:

AGEX-BAT1 for Type 2 diabetes; AGEX-VASC1 for metabolic imbalances in aging; and AGEX-iTR1547 for the treatment of congestive heart failure, all under preclinical testing.

4. Ovid Therapeutics Inc. (OVID)

Gained 14.20% to close Tuesday's trading at $1.93.

News: No news

Pipeline & Near-term Catalysts:

-- A pivotal phase III trial of OV101 for Angelman Syndrome, dubbed NEPTUNE, is expected to be initiated with the first patient enrolling in 2H19. -- A phase II trial of OV101 for Fragile X Syndrome, dubbed ROCKET, continues to enroll patients and results are expected in 2H19. -- A phase II trial of OV935 in people with Dup15q syndrome or CDKL5 Deficiency Disorder, dubbed ARCADE, continues to enroll - with completion of enrollment expected in 2H19. -- A phase II trial of OV935 in people with Dravet syndrome or Lennox-Gastaut syndrome continues to enroll.

5. AzurRx BioPharma Inc. (AZRX)

Gained 13.38% to close Tuesday's trading at $1.78.

News: No news

Near-term Catalyst:

-- A phase II study of MS1819-SD in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency, dubbed OPTION, is underway, with top-line data expected in Summer 2019.